Ellen Chiniara Biography and Net Worth

Chief Legal Officer and Corporate Secretary of Kymera Therapeutics

Prior to Kymera, Ellen served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Alexion Pharmaceuticals, where she was responsible for all legal, intellectual property and governance matters, and was the executive sponsor of the Corporate Social Responsibility program, until the company’s acquisition by AstraZeneca in 2021. In this role, she built and transformed the legal function, mission, and culture at the company by focusing on solutions, developing and mentoring talent, and implementing new technology and infrastructure. Before Alexion, Ellen was General Counsel at Alere, Inc., a point-of-care diagnostics company, where she spent over a decade managing various legal, government affairs, and governance functions through rapid growth and significant acquisitions globally. Earlier in her career, she was responsible for the legal function of the US neurology division at Serono and was a Partner at the law firm Hale and Dorr LLP.

Ellen currently serves as a member of the Board of Directors at Compass Therapeutics. She graduated magna cum laude from Bryn Mawr College and earned her Juris Doctor from Stanford University School of Law.

What is Ellen Chiniara's net worth?: The estimated net worth of Ellen Chiniara is at least $1.54 million as of January 4th, 2024. Ms. Chiniara owns 34,205 shares of Kymera Therapeutics stock worth more than $1,538,541 as of November 23rd. This net worth evaluation does not reflect any other assets that Ms. Chiniara may own. Additionally, Ms. Chiniara receives an annual salary of $640,350.00 as Chief Legal Officer and Corporate Secretary at Kymera Therapeutics. Learn More about Ellen Chiniara's net worth.
How old is Ellen Chiniara?: Ms. Chiniara is currently 65 years old. There are 4 older executives and no younger executives at Kymera Therapeutics. Learn More on Ellen Chiniara's age.
What is Ellen Chiniara's salary?: As the Chief Legal Officer and Corporate Secretary of Kymera Therapeutics, Inc., Ms. Chiniara earns $640,350.00 per year. There are 3 executives that earn more than Ms. Chiniara. The highest earning executive at Kymera Therapeutics is Dr. Nello Mainolfi M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,080,000.00 per year. Learn More on Ellen Chiniara's salary.
How do I contact Ellen Chiniara?: The corporate mailing address for Ms. Chiniara and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]. Learn More on Ellen Chiniara's contact information.
Has Ellen Chiniara been buying or selling shares of Kymera Therapeutics?: Ellen Chiniara has not been actively trading shares of Kymera Therapeutics during the past quarter. Most recently, Ellen Chiniara sold 3,295 shares of the business's stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $22.58, for a transaction totalling $74,401.10. Following the completion of the sale, the insider now directly owns 34,205 shares of the company's stock, valued at $772,348.90. Learn More on Ellen Chiniara's trading history.
Who are Kymera Therapeutics' active insiders?: Kymera Therapeutics' insider roster includes Jeffrey Albers (Director), Bruce Booth (Director), Richard Chesworth (Insider), Ellen Chiniara (Chief Legal Officer and Corporate Secretary), Jared Gollob (Insider), Bruce Jacobs (CFO), and Nello Mainolfi (CEO). Learn More on Kymera Therapeutics' active insiders.
Are insiders buying or selling shares of Kymera Therapeutics?: In the last twelve months, insiders at the sold shares 16 times. They sold a total of 1,008,191 shares worth more than $40,176,324.03. The most recent insider tranaction occured on September, 17th when Director Pamela Esposito sold 13,500 shares worth more than $651,780.00. Insiders at Kymera Therapeutics own 15.8% of the company. Learn More about insider trades at Kymera Therapeutics.
Information on this page was last updated on 9/17/2024.

Ellen Chiniara Insider Trading History at Kymera Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/4/2024	Sell	3,295	$22.58	$74,401.10	34,205

Ellen Chiniara Buying and Selling Activity at Kymera Therapeutics

Kymera Therapeutics Company Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $44.98

$43.28

$45.94

50 Day Range

MA: $46.97

$41.96

$52.40

2 Week Range

Now: $44.98

$18.89

$53.27

Volume

559,364 shs

Average Volume

427,946 shs

Market Capitalization

$2.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.21

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

Ellen Chiniara Biography and Net Worth

What is Ellen Chiniara's net worth?

How old is Ellen Chiniara?

What is Ellen Chiniara's salary?

How do I contact Ellen Chiniara?

Has Ellen Chiniara been buying or selling shares of Kymera Therapeutics?

Who are Kymera Therapeutics' active insiders?

Are insiders buying or selling shares of Kymera Therapeutics?